GRAIL, Inc. (NASDAQ:GRAL) Given Consensus Rating of “Hold” by Analysts

GRAIL, Inc. (NASDAQ:GRAL) has been assigned an average recommendation of “Hold” from the eight ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $67.8750.

Several brokerages have commented on GRAL. Guggenheim dropped their price target on GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a research note on Saturday. Robert W. Baird set a $70.00 price target on GRAIL in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a research note on Tuesday, April 21st. Finally, Mizuho assumed coverage on GRAIL in a research note on Friday, April 10th. They issued a “neutral” rating and a $58.00 target price for the company.

Insider Activity

In other news, President Joshua J. Ofman sold 61,665 shares of the stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total value of $3,078,316.80. Following the completion of the sale, the president owned 371,216 shares in the company, valued at approximately $18,531,102.72. This trade represents a 14.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert P. Ragusa sold 123,502 shares of the stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $6,165,219.84. Following the completion of the sale, the chief executive officer owned 518,582 shares of the company’s stock, valued at approximately $25,887,613.44. This trade represents a 19.23% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 310,267 shares of company stock worth $15,485,396. 1.85% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On GRAIL

A number of large investors have recently modified their holdings of GRAL. Fifth Third Bancorp grew its stake in shares of GRAIL by 15,733.3% in the first quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after buying an additional 472 shares in the last quarter. N.E.W. Advisory Services LLC acquired a new stake in shares of GRAIL in the fourth quarter valued at about $26,000. Comerica Bank grew its stake in GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in GRAIL during the 4th quarter valued at approximately $28,000. Finally, Geneos Wealth Management Inc. grew its stake in GRAIL by 160.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock valued at $30,000 after purchasing an additional 360 shares in the last quarter.

GRAIL Price Performance

Shares of NASDAQ:GRAL opened at $61.64 on Tuesday. The firm has a market capitalization of $2.65 billion, a PE ratio of -5.94 and a beta of 3.03. The business has a 50-day moving average of $51.05 and a two-hundred day moving average of $78.44. GRAIL has a 12 month low of $29.95 and a 12 month high of $118.84.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, topping the consensus estimate of ($2.76) by $0.47. The company had revenue of $40.79 million during the quarter, compared to analyst estimates of $39.16 million. GRAIL had a negative return on equity of 16.63% and a negative net margin of 253.22%. As a group, research analysts anticipate that GRAIL will post -11.09 earnings per share for the current year.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.